ご寄付はこちら

論文

48. JACCRO CC-13

UPDATE : 2024/11/26

Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial
Manabu Shiozawa, Yu Sunakawa, Takanori Watanabe, Hirofumi Ota, Hisateru Yasui, Taichi Yabuno, Mitsuyoshi Tei, Mitsugu Kochi, Dai Manaka, Hisatsugu Ohori, Tatsuro Yamaguchi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii and Akihito Tsuji
Nature Communications 2024; 15: 10217
https://doi.org/10.1038/s41467-024-54460-2

47. JACCRO GC-08

UPDATE : 2024/09/01

Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08)
Yu Sunakawa, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Eisuke Inoue, Wataru Ichikawa, Masashi Fujii
The Oncologist 2024; 29(8): e997–e1002.
https://doi.org/10.1093/oncolo/oyae056

46. JACCRO GC-10

UPDATE : 2024/02/01

Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials
Hiroyuki Arai, Madoka Takeuchi, Wataru Ichikawa, Kohei Shitara, Yu Sunakawa, Koji Oba, Wasaburo Koizumi, Yuh Sakata, Hiroshi Furukawa, Yasuhide Yamada, Masahiro Takeuchi, Masashi Fujii
Cancer Medicine 2024; 13(1): e6818
doi: 10.1002/cam4.6818
https://doi.org/10.1002/cam4.6818

45. JACCRO CC-16

UPDATE : 2023/10/10

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16
Hisateru Yasui, Yoshihiro Okita, Masato Nakamura, Tamotsu Sagawa, Takanori Watanabe, Kozo Kataoka, Dai Manaka, Kazuhiro Shiraishi, Naoya Akazawa, Tatsuya Okuno, Takaya Shimura, Manabu Shiozawa, Yu Sunakawa, Hirofumi Ota, Masahito Kotaka, Hiroyuki Okuyama, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii and Akihito Tsuji
ESMO Open 2023; 8(5): 101636
doi: https://doi.org/10.1007/s10120-023-01419-9
https://www.esmoopen.com/article/S2059-7029(23)00871-2/fulltext

44. JACCRO GC-07

UPDATE : 2023/12/25

Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study
Yasuhiro Kodera, Kazuhiro Yoshida, Mitsugu Kochi, Takeshi Sano, Wataru Ichikawa, Yoshihiro Kakeji, Yu Sunakawa, Masahiro Takeuchi & Masashi Fujii
Gastric Cancer 2023, 26:1063–8
doi: https://doi.org/10.1007/s10120-023-01419-9
https://doi.org/10.1007/s10120-023-01419-9

43. JACCRO BC-03

UPDATE : 2023/09/13

Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)
Kokoro Kobayashi, Norikazu Masuda, Toshiro Mizuno, Kayo Miura, Yutaka Tokuda, Tetsuhiro Yoshinami, Hidetoshi Kawaguchi, Shoichiro Ohtani, Toshiaki Saeki, Masakazu Toi, Masahiro Takeuchi & Yoshinori Ito
Breast Cancer Research and Treatment 2023; 201: 409–15
doi: https://doi.org/10.1007/s10549-023-07030-x
https://link.springer.com/article/10.1007/s10549-023-07030-x

42. JACCRO CC-18

UPDATE : 2023/06/14

The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF-mutated metastatic colorectal cancer
Chiaki Inagaki, Ryo Matoba, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Eisuke Inoue, Kei Muro, Wataru Ichikawa, Masashi Fujii and Yu Sunakawa
Future Oncology 2023; 19: 1165-74
doi: https://doi.org/10.2217/fon-2023-0209
https://doi.org/10.2217/fon-2023-0209

41. JACCRO GC-09

UPDATE : 2023/06/01

A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)
Ryohei Kawabata, Naoki Izawa, Takahisa Suzuki, Yoshio Nagahisa, Kazuhiro Nishikawa, Masazumi Takahashi, Masato Nakamura, Atsushi Ishiguro, Hiroo Katsuya, Jun Hihara, Dai Manaka, Yuji Negoro, Akihito Tsuji, Takao Takahashi, Mitsugu Kochi, Mizutomo Azuma, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa and Masashi Fujii
Targeted Oncology 2023; 18: 359–68
doi: https://doi.org/10.1007/s11523-023-00961-x
https://link.springer.com/article/10.1007/s11523-023-00961-x

40. JACCRO GC-08AR

UPDATE : 2023/03/08

Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial
Hisato Kawakami, Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Kenta Noda, Toshiyuki Sato, Chihiro Suminaka, Mami Yamaki, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Hiroshi Yabusaki, Jin Matsuyama, Masazumi Takahashi, Akitaka Makiyama, Hidetoshi Hayashi, Kenji Chamoto, Tasuku Honjo, Kazuhiko Nakagawa, Wataru Ichikawa, Masashi Fujii
European Journal of Cancer 2023; 184: 10-20
doi: https://doi.org/10.1016/j.ejca.2023.02.003
https://doi.org/10.1016/j.ejca.2023.02.003

39. JACCRO CC-11

UPDATE : 2022/06/10

Dynamic changes in RAS gene status in circulating tumour DNA: a phase II trial of first-line FOLFOXIRI plus bevacizumab for RAS-mutant metastatic colorectal cancer (JACCRO CC-11)
ESMO Open 2022; 7(3): 100512
doi: 10.1016/j.esmoop.2022.100512
https://www.sciencedirect.com/science/article/pii/S2059702922001326

38. JACCRO CC-07

UPDATE : 2022/05/13

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
Hiroaki Tanioka, Ken Shimada, Akihito Tsuji, Mitsugu Kochi, Ho Min Kim, Takao Takahashi, Tadamichi Denda, Akinori Takagane, Takanori Watanabe, Masahito Kotaka, Masato Nakamura, Yu Sunakawa, Masahiro Takeuchi, Wataru Ichikawa and Masashi Fujii
Anticancer Res 2022; 42: 2675-81
doi: 10.21873/anticanres.15745.
https://ar.iiarjournals.org/content/42/5/2675.long

37. JACCRO CC-09

UPDATE : 2021/11/07

Phase II study of third-line Panitumumab rechallenge in patients with metastatic wild-type KRAS colorectal cancer who obtained clinical benefit from first-line Panitumumab-based chemotherapy: JACCRO CC-09.
Target Oncol. 2021; 16: 753-60
DOI: 10.1007/s11523-021-00845-y
https://doi.org/10.1007/s11523-021-00845-y

36. JACCRO CC-12

UPDATE : 2021/10/13

18F-FDG-PET/CT as an imaging biomarker for regorafenib efficacy in metastatic colorectal cancer (JACCRO CC-12)
Masato Nakamura, Hironaga Satake, Tamotsu Sagawa, Akinori Takagane, Takashi Sekikawa, Kazuhiro Oguchi, Tomohito Kaji, Masahiro Takeuchi . Wataru Ichikawa, Masashi Fujii
Oncol Ther 2021; 9: 635-45
DOI: 10.1007/s40487-021-00173-1
https://doi.org/10.1007/s40487-021-00173-1

35. JACCRO GC-08(DELIVER)

UPDATE : 2021/08/31

Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)
Yoshikazu Takahashi, Yu Sunakawa, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yosuke Kito, Yusuke Akamaru, Masazumi Takahashi, Hiroshi Yabusaki, Jin Matsuyama, Akitaka Makiyama, Masahiro Tsuda, Takahisa Suzuki, Hisateru Yasui, Ryo Matoba, Hisato Kawakami, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa and Masashi Fujii
Gastric Cancer 2022; 25: 235–44
DOI: 10.1007/s10120-021-01237-x
https://doi.org/10.1007/s10120-021-01237-x

34. JACCRO GC-07(START-2)

UPDATE : 2021/08/31

Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer: JACCRO GC-07
Yoshihiro Kakeji, Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Takeshi Sano, Wataru Ichikawa, Sang-Woong Lee, Kazushige Shibahara, Toshio Shikano, Masato Kataoka, Atsushi Ishiguro, Hitoshi Ojima, Yoshinori Sakai, Nobuyuki Musha, Tsunenobu Takase, Taisei Kimura, Masahiro Takeuchi, Masashi Fujii
Gastric Cancer 2022; 25: 188–96
DOI: 10.1007/s10120-021-01224-2
https://doi.org/10.1007/s10120-021-01224-2

33. JACCRO CC-05/CC-06AR

UPDATE : 2020/10/15

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
Nico B. Volz, Diana L. Hanna, Sebastian Stintzing, Wu Zhang, Dongyun Yang, Shu Cao, Yan Ning, Satoshi Matsusaka, Yu Sunakawa, Martin D. Berger, Chiara Cremolini, Fotios Loupakis, Alfredo Falcone and Heinz-Josef Lenz
Cancers 2020, 12(10), 2947
 DOI: 10.3390/cancers12102947
 https://www.mdpi.com/2072-6694/12/10/2947

32. JACCRO CC-08

UPDATE : 2020/10/15

Phase II study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08
Toshiki Masuishi, Akihito Tsuji, Masahito Kotaka, Masato Nakamura, Mitsugu Kochi, Akinori Takagane, Ken Shimada, Tadamichi Denda, Yoshihiko Segawa, Hiroaki Tanioka, Hiroki Hara, Tamotsu Sagawa, Takanori Watanabe, Takao Takahashi, Yuji Negoro, Dai Manaka, Hideto Fujita, Takeshi Sudo, Masahiro Takeuchi, Wataru Ichikawa, and Masashi Fuji
British Journal of Cancer 2020; 123: 1490–5
 DOI: 10.1038/s41416-020-01042-w
 https://www.nature.com/articles/s41416-020-01042-w#citeas

31. JACCRO CC-08AR、JACCRO CC-09AR

UPDATE : 2020/07/31

RAS Mutations in Circulating Tumor DNA and Clinical Outcomes of Rechallenge Treatment With Anti-EGFR Antibodies in Patients With Metastatic Colorectal Cancer
Yu Sunakawa, Masato Nakamura, Masahiro Ishizaki, Masato Kataoka, Hironaga Satake, Masaki Kitazono, Hideyuki Yanagisawa, Yasuyuki Kawamoto, Hidekazu Kuramochi, Hisatsugu Ohori, Michio Nakamura, Fumiyo Maeda, Chihiro Komeno, Tomoko Sonezaki, Masahiro Takeuchi, Masashi Fujii, Takayuki Yoshino, Akihito Tsuji and Wataru Ichikawa
JCO Precision Oncology 2020; 4: 898-911
DOI: https://doi.org/10.1200/PO.20.00109
https://ascopubs.org/doi/full/10.1200/PO.20.00109 

30. JACCRO GC-08

UPDATE : 2019/10/29

DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer
Yu Sunakawa, Eisuke Inoue, Ryo Matoba, Hisato Kawakami, Yoshiharu Sato, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa, Masashi Fujii
Future ONCOLOGY 2019; 15(21): 2441-7
DOI: https://doi.org/10.2217/fon-2019-0167
https://www.futuremedicine.com/doi/10.2217/fon-2019-0167

29. JACCRO CC-04

UPDATE : 2019/04/16

Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial)
Keisaku Kondo, Satoshi Matsusaka, Soichiro Ishihara, Hisanaga Horie, Keisuke Uehara, Masahiko Oguchi, Keiko Murafushi, Masashi Ueno, Nobuyuki Mizunuma, Taiju Shimbo, Daiki Kato, Junji Okuda, Yojiro Hashiguchi, Masanori Nakazawa, Eiji Sunami, Kazushige Kawai, Hideomi Yamashita, Tohru Okada, Yuichi Ishikawa, Masashi Fujii, Toshifusa Nakajima
Radiotherapy and Oncology 2019; 134: 199–203
 DOI: https://doi.org/10.1016/j.radonc.2019.02.006
 https://www.thegreenjournal.com/article/S0167-8140(19)30073-8/fulltext

28. JACCRO GC-07(START-2)

UPDATE : 2019/04/16

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial
Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Wataru Ichikawa, Yoshihiro Kakeji, Takeshi Sano, Narutoshi Nagao, Masazumi Takahashi, Akinori Takagane, Takuya Watanabe, Masahide Kaji, Hiroshi Okitsu,  Takashi Nomura, Takanori Matsui, Takaki Yoshikawa, Jin Matsuyama, Makoto Yamada, Seiji Ito, Masahiro Takeuchi, and Masashi Fujii
J Clin Oncol 2019; 37:1296-304
 DOI: https://doi.org/10.1200/JCO.18.01138
 https://ascopubs.org/doi/full/10.1200/JCO.18.01138

27. JACCROの成果と展望

UPDATE : 2019/03/07

JACCRO(日本がん臨床試験推進機構)の成果と展望
 藤井雅志、市川度、竹内正弘、山口俊晴、髙久史麿
 腫瘍内科 2019; 2(23),101-109
 http://www.kahyo.com/item/ON201902-232

26. JACCRO CC-11

UPDATE : 2019/01/15

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
Yu Sunakawa, Hironaga Satake, Wataru Ichikawa
World J Gastrointest Oncol. 2018; 10(12): 528-31
 doi: 10.4251/wjgo.v10.i12.528.
 https://www.wjgnet.com/1948-5204/full/v10/i12/528.htm

25. JACCRO CC-05/CC-06AR_B

UPDATE : 2018/10/05

Tumor sidedness and enriched gene groups for efficacy of first-line cetuximab treatment in metastatic colorectal cancer
Yu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, Wu Zhang, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Yoshihiko Segawa, Hiroaki Tanioka, Yuji Negoro, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Masashi Fujii, Wataru Ichikawa
Mol Cancer Ther 2018; 17(12): 2788-95
DOI: 10.1158/1535-7163.MCT-18-0694
https://mct.aacrjournals.org/content/17/12/2788.

24. JACCRO CC-05/CC-06AR

UPDATE : 2018/08/27

Immune-related genes to dominate neutrophil-lymphocyte ratio (NLR) associated with survival of cetuximab treatment in metastatic colorectal cancer
 Yu Sunakawa, Dongyun Yang, Shu Cao, Wu Zhang, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Akihito Tsuji, Takehiro Takahashi, Hiroaki Tanioka, Yuji Negoro, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Tetsuya Eto, Masashi Fujii, Wataru Ichikawa, Heinz-Josef Lenz
 Clinical Colorectal Cancer 2018; 17(4), e741–9
 DOI: https://doi.org/10.1016/j.clcc.2018.08.002
 https://www.clinical-colorectal-cancer.com/article/S1533-0028(18)30353-0/abstract

23. JACCRO CC-11

UPDATE : 2018/04/17

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11
Hironaga Satake, Yu Sunakawa, Yuji Miyamoto, Masato Nakamura, Hiroshi Nakayama, Manabu Shiozawa, Akitaka Makiyama, Kazuma Kobayashi, Yutaro Kubota, Misuzu Mori, Masahito Kotaka, Akinori Takagane, Masahiro Gotoh,
Masahiro Takeuchi, Masashi Fujii, Wararu Ichikawa, Takashi Sekikawa
Oncotarget 2018; 9(27), 18811-20
DOI: https://doi.org/10.18632/oncotarget.24702
https://www.oncotarget.com/article/25775/

22. JACCRO CC-14

UPDATE : 2018/08/27

Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
 Hironaga Satake, Akihito Tsuji, Masato Nakamura, Masaaki Ogawa, Takeshi Kotake, Yukimasa Hatachi, Hisateru Yasui, Akinori Takagane, Yoshihiro Okita, Kumi Nakamura, Toshihide Onikubo, Masahiro Takeuchi, Masashi Fujii:
International Journal of Clinical Oncology 2018; 3(32), 490-6
 DOI: 10.1007/s10147-017-1228-5
 http://link.springer.com/article/10.1007/s10147-017-1228-5

21. JACCRO GC-06

UPDATE : 2017/04/24

Multicenter phase II study of trastuzumab plus S 1 alone in elderly patients with HER2 positive advanced gastric cancer (JACCRO GC-06)
Yutaka Kimura, Masashi Fujii, Toshiki Masuishi, Kazuhiro Nishikawa, Chikara Kunisaki, Satoshi Matsusaka, Yoshihiko Segawa, Masato Nakamura, Kinro Sasaki, Narutoshi Nagao, Yukimasa Hatachi, Yasuhiko Yuasa, Shinya Asami, Masahiro Takeuchi, Hiroshi Furukawa, Toshifusa Nakajima on behalf of the JACCRO GC-06 Study Group
Gastric Cancer 2018; 21:421–27
 DOI: 10.1007/s10120-017-0766-x
 https://link.springer.com/article/10.1007%2Fs10120-017-0766-x

20. JACCRO CC-05、JACCRO CC-06

UPDATE : 2017/09/15

CEA response and depth of response (DpR) to predict clinical utcomes of first-line cetuximab treatment for metastatic colorectal cancer
Y. Sunakawa, A. Tsuji, T. Denda, Y. Segawa, Y. Negoro, K. Shimada, M. Kochi, M. Nakamura, M. Kotaka, H. Tanioka, A. Takagane, S. Tani, T. Yamaguchi, T. Watanabe, M. Takeuchi, M. Fuji, W. Ichikawa
 Targeted Oncology 2017; 12(6), 787-94
 DOI: https://doi.org/10.1007/s11523-017-0527-0
 https://link.springer.com/article/10.1007/s11523-017-0527-0

19. JACCRO CC-05、JACCRO CC-06

UPDATE : 2017/05/19

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
Annals of Oncology 2017; 28 (8): 2030?31
Y. Sunakawa, A. Tsuji, M. Fujii, W. Ichikawa
 DOI: https://doi.org/10.1093/annonc/mdx231
 https://academic.oup.com/annonc/article-abstract/28/8/2030/3798690

18. JACCRO CC-05、JACCRO CC-06

UPDATE : 2016/10/12

Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials.
Yu Sunakawa, Wataru Ichikawa, Akihito Tsuji, Tadamichi Denda, Yoshihiko Segawa, Yuji Negoro, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Hiroaki Tanioka, Akinori Takagane, Satoshi Tani, Tatsuro Yamaguchi, Takanori Watanabe, Masahiro Takeuchi, Masashi Fujii, Toshifusa Nakajima
Clinical Colorectal Cancer 2017; 16(3): e171-180
 DOI: http://dx.doi.org/10.1016/j.clcc.2016.09.010
 http://www.clinical-colorectal-cancer.com/article/S1533-0028(16)30204-3/abstract

17. JACCRO CC-05/CC-06AR

UPDATE : 2016/10/12

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.
A Sebio, S Stintzing, V Heinemann, Y Sunakawa, W Zhang, W Ichikawa, A Tsuji, T Takahashi, A Parek, D Yang, S Cao, Y Ning, S Stremitzer, S Matsusaka, S Okazaki, A Barzi, M D Berger and H-J Lenz.
The Pharmacogenomics Journal 2018; 18: 43–8
 DOI:10.1038/tpj.2016.69
 https://www.nature.com/articles/tpj201669

16. JACCRO CC-05

UPDATE : 2016/06/20

Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX plus cetuximab (JACCRO CC-05)
A. Tsuji, Y. Sunakawa, W. Ichikawa, M. Nakamura, M. Kochi, T. Denda, T. Yamaguchi, K. Shimada, A. Takagane, S. Tani, M. Kotaka, H. Kuramochi, K. Furushima, J. Koike, Y. Yonemura, M. Takeuchi, M. Fujii, T. Nakajima.
Targeted Oncology 2016; 11(6): 799-806
 DOI: 10.1007/s11523-016-0445-6
 https://link.springer.com/article/10.1007/s11523-016-0445-6

15. JACCRO CC-05/CC-06AR

UPDATE : 2016/06/20

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Y. Sunakawa, D. Yang, M. Moran, S. H. Astrow, A. Tsuji, C. Stephens, W. Zhang, S. Cao, T. Takahashi, T. Denda, K. Shimada, M. Kochi, M. Nakamura, M. Kotaka,Y. Segawa, T. Masuishi, M. Takeuchi, M. Fujii, T. Nakajima, W. Ichikawa, H. Lenz.
Cancer Biology & Therapy 2016: 17(7): 751-9
 DOI:10.1080/15384047.2016.1178426
 https://www.tandfonline.com/doi/full/10.1080/15384047.2016.1178426

14. JACCRO GC-04

UPDATE : 2016/04/21

Exploratory phase II trial in a multicenter setting to evaluate the clinical value of chemosensitivity test in patients with gastric cancer (JACCRO GC-04, Kubota memorial trial)
N. Tanigawa, H. Yamaue, S. Ohyama, S. Sakuramoto, T. Inada, Y. Kodera, Y. Kitagawa, K. Omura, M. Terashima, Y. Sakata, A. Nashimoto, T. Yamaguchi, K. Chin, E. Nomura, S.W. Lee, M. Takeuchi, M. Fujii, T. Nakajima
Gastric Cancer 2016; 19(2): 350-60
 DOI 10.1007/s10120-015-0506-z
 https://link.springer.com/article/10.1007/s10120-015-0506-z

13. JACCRO GY-01

UPDATE : 2016/02/09

Phase II study of concurrent chemoradiotherapy with weekly cisplatin and paclitaxel in patients with locally advanced uterine cervical cancer: The JACCRO GY-01 trial.
K. Umayahara, M. Takekuma, Y. Hirashima, S. Noda, T. Ohno, E. Miyagi, F. Hirahara, E. Hirata, E. Kondo, T. Tabata, Y. Nagai, Y. Aoki, M. Wakatsuki, M. Takeuchi, T. Toita, N. Takeshima, K. Takizawa
Gynecol Oncol 2016; 140 (2): 253-258
Doi: 10.1016/j.ygyno.2015.12.008

12. JACCRO CC-04

UPDATE : 2015/11/10

A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
S. Matsusaka, S. Ishihara, K. Kondo, H. Horie, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shimbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, Y. Ishikawa, T. Nakajima, T. Watanabe.
 Radiother Oncol. 2015 Aug;116(2):209-13.
 DOI: 10.1016/j.radonc.2015.08.002.
 http://www.thegreenjournal.com/article/S0167-8140(15)00421-1/abstract

11. JACCRO GC-05

UPDATE : 2015/11/10

Phase II/III study of second-line chemotherapy comparing irinotecan alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
K. Tanabe, M. Fujii, K. Nishikawa, C. Kunisaki, A. Tsuji, N. Matsuhashi, A. Takagane, T. Ohno, T. Kawase, M. Kochi, K. Yoshida, Y. Kakeji, W. Ichikawa, K. Chin, M. Terashima, M. Takeuchi and T. Nakajima on behalf of the JACCRO GC-05 study group.
Ann Oncol (2015) 26 (9): 1916-1922
 DOI: 10.1093/annonc/mdv265
 https://academic.oup.com/annonc/article/26/9/1916/189421

10. JACCRO CC-04

UPDATE : 2015/11/10

A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).
S. Ishihara, S. Matsusaka, K. Kondo, H. Horie, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shinbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, Y. Ishikawa, T. Nakajima and T. Watanabe.
 Radiation Oncology (2015) 10:24
 DOI 10.1186/s13014-015-0333-8
 https://doi.org/10.1186/s13014-015-0333-8

9. JACCRO GC-03

UPDATE : 2015/11/10

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
W. Koizumi, Y. H. Kim, M. Fujii, H. K. Kim, H. Imamura, K. H. Lee, T. Hara, H. C. Chung, T. Satoh, J. Y. Cho, H. Hosaka, A. Tsuji, A. Takagane, M. Inokuchi, K. Tanabe, T. Okuno, M. Ogura, K. Yoshida, M. Takeuchi, T. Nakajima; JACCRO and KCSG Study Group.
J Cancer Res Clin Oncol 2014; 140: 319-28
 DOI: 10.1007/s00432-013-1563-5
 https://link.springer.com/article/10.1007/s00432-013-1563-5

8. JACCRO CC-03

UPDATE : 2013/12/01

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
M. Kochi, Y. Akiyama, T. Aoki, K. Hagiwara, T. Takahashi, K. Hironaka, F. Teranishi, F. Osuka, M. Takeuchi, M. Fujii, T. Nakajima.
Cancer Chemother Pharmacol 2013; 72, 1097-102
 DOI: 10.1007/s00280-013-2292-9
 https://link.springer.com/article/10.1007/s00280-013-2292-9

7. JACCRO PC-01

UPDATE : 2012/06/07

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
 Ozaka M, Matsumura Y, Ishii H, Omuro Y, Itoi T, Mouri H, Hanada K, Kimura Y, Maetani I, Okabe Y, Tani M, Ikeda T, Hijioka S, Watanabe R, Ohoka S, Hirose Y, Suyama M, Egawa N, Sofuni A, Ikari T, Nakajima T.
 Cancer Chemother Pharmacol 2012; 69 : 1197-204.
 DOI: https://doi.org/10.1007/s00280-012-1822-1
 https://link.springer.com/article/10.1007/s00280-012-1822-1

6. JACCRO LC-01

UPDATE : 2011/09/01

Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study)
 Imamura, F. , Nishio, M. , Noro, R. , Tsuboi, M., Ikeda, N. Inoue, A. , Ohsaki, Y. , Kimura, Y. , Nishino, K., Uchida, J., Horai, T. 
 Chemotherapy 2011;57:357-62
 https://doi.org/10.1159/000330481

5. 統計学の基礎知識と解析ソフト

UPDATE : 2011/09/01

 統計学の基礎知識と解析ソフト
がん研有明病院 中島 聰總、防衛医科大学校 佐藤弘樹,
Drug Delivery System Vol.26 No2, 148-154(2011)

4. 日本がん臨床試験推進機構(JACCRO)の紹介

UPDATE : 2011/09/01

日本がん臨床試験推進機構(JACCRO)
中島 聰總、山口 俊晴、藤井 雅志、島田 安博、竹内 正弘
腫瘍内科 Vol.6 No.4, 305-311(2010)

3. JACCRO CC-02

UPDATE : 2011/09/01

Phase II study of FOLFOX4 with “wait and go” strategy as Wrst-line treatment for metastatic colorectal cancer
 Mitsugu Kochi, Wataru Ichikawa, Eiji Meguro, Hiroyuki Shibata, Takuji Fukui, Michitaka Nagase, Yutaka Hoshino, Masahiro Takeuchi,  Masashi Fujii, Toshifusa Nakajima.
 Cancer Chemother Pharmacol 2011;68:1215-1222
 https://link.springer.com/article/10.1007/s00280-011-1605-0

2. JACCRO GC-01

UPDATE : 2011/09/01

A phaseⅡ study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for serosa-positive gastric cancer (JACCRO GC-01 study);T.Yoshikawa, K.Omura, O.Kobayashi, A.Nashimoto, A.Takabayashi, T.Yamada, H.Yamaue, M.Fujii, T.Yamaguchi, T.Nakajima..  Europian J Surg Oncol 2010 ; 36 : 546-551 (2010)
 DOI: https://doi.org/10.1016/j.ejso.2010.04.011
 http://www.ejso.com/article/S0748-7983(10)00099-5/fulltext

1. FLADS systemの紹介

UPDATE : 2011/09/01

FLADS systemの紹介抗癌剤開発臨床試験へのJACCROの取り組み - FLADS(Flexible License Assisted Data Server)systemによるsupport -
中島聰總、山口俊晴、藤井雅志、島田安博、福井巌、曽根三郎、鶴尾隆、竹内正弘、小川一誠、青柳宏.
外科治療 Vol.97 No.5, 517-523(2007)